Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Nikhil Lalwani, President and CEO of ANI Pharmaceuticals INC (NASDAQ:ANIP), a company with a market capitalization of $1.81 billion that has seen its stock surge over 52% in the past six months, sold 56,960 shares of common stock on August 12, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold in multiple transactions at prices ranging from $84.40 to $87.47, resulting in a total transaction value of $4,894,572. The weighted average sales price was $85.93.
Following the transaction, Lalwani directly owns 411,219 shares of ANI Pharmaceuticals INC.
In other recent news, ANI Pharmaceuticals reported strong second-quarter 2025 financial results that exceeded market expectations. The company achieved an adjusted non-GAAP earnings per share of $1.80, surpassing the forecast of $1.40. Revenue for the quarter reached $211.4 million, exceeding the anticipated $187.34 million. The Cortrophin Gel product line significantly contributed to this performance, generating $81.6 million in revenue, which represents a 66% year-over-year growth. As a result of these strong results, ANI Pharmaceuticals raised its guidance for revenue, adjusted EBITDA, and EPS.
Following these developments, H.C. Wainwright raised its price target for ANI Pharmaceuticals to $93, maintaining a Buy rating. Truist Securities also increased its price target to $77, while keeping a Hold rating on the stock. These adjustments reflect the company’s robust performance and positive outlook. The recent results and analyst actions indicate a strong position for ANI Pharmaceuticals in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.